Singer Philipp, Feldon Joram, Yee Benjamin K
Laboratory of Behavioural Neurobiology, Swiss Federal Institute of Technology, Schorenstrasse 16, 8603 Schwerzenbach, Switzerland.
Psychopharmacology (Berl). 2009 Jan;202(1-3):371-84. doi: 10.1007/s00213-008-1286-5. Epub 2008 Aug 29.
Inhibition of the glycine transporter 1 (GlyT1) activity increases extra-cellular glycine availability in the CNS. At glutamatergic synapses, increased binding to the glycine-B site located in the N-methyl-D-aspartate receptor (NMDAR) can enhance neurotransmission via NMDARs. Systemic treatment of 2-chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride (SSR504734), a selective GlyT1 inhibitor, is effective against social recognition impairment induced by neonatal phencyclidine treatment and enhances pre-pulse inhibition in a mouse strain (DBA/2) with intrinsic sensorimotor gating deficiency, suggesting that SSR504734 may be an effective cognitive enhancer.
The objective of the study was to examine if SSR504734 exhibits a promnesic effect on working memory function in wild-type C57BL/6 mice using an automatic continuous alternation task.
Hungry mice were trained to alternate their nose pokes between two food magazines across successive discrete trials in an operant chamber in order to obtain food reward. Correct choice on a given trial thus followed a non-matching or win-shift rule in relation to the preceding trial, with manipulation of the demand on memory retention, by varying the delay between successive trials.
Pre-treatment with SSR504734 (30 mg/kg, i.p.) improved choice accuracy when the delay from the previous trial was extended to 12-16 s. Furthermore, a dose-response analysis (3, 10, 30 mg/kg) revealed a clear dose-dependent efficacy of the drug: 3 mg/kg was without effect, whilst 10 mg/kg led to an intermediate enhancement in performance.
The present findings represent the first demonstration of the promnesic effects of SSR504734 under normal physiological conditions, lending further support to the suggestion of its potential as a cognitive enhancer.
抑制甘氨酸转运体1(GlyT1)的活性可增加中枢神经系统中细胞外甘氨酸的可用性。在谷氨酸能突触处,与位于N-甲基-D-天冬氨酸受体(NMDAR)上的甘氨酸B位点的结合增加,可通过NMDAR增强神经传递。2-氯-N-[(S)-苯基[(2S)-哌啶-2-基]甲基]-3-三氟甲基苯甲酰胺盐酸盐(SSR504734)是一种选择性GlyT1抑制剂,其全身治疗可有效对抗新生期苯环利定治疗引起的社会认知障碍,并增强具有内在感觉运动门控缺陷的小鼠品系(DBA/2)的前脉冲抑制,这表明SSR504734可能是一种有效的认知增强剂。
本研究的目的是使用自动连续交替任务,研究SSR504734对野生型C57BL/6小鼠工作记忆功能是否具有记忆增强作用。
饥饿的小鼠在操作箱中经过连续离散试验,训练其在两个食物盒之间交替戳鼻,以获得食物奖励。因此,在给定试验中的正确选择遵循与前一试验相关的不匹配或赢-转移规则,并通过改变连续试验之间的延迟来操纵对记忆保持的要求。
当与前一试验的延迟延长至12 - 16秒时,SSR504734(30毫克/千克,腹腔注射)预处理可提高选择准确性。此外,剂量反应分析(3、10、30毫克/千克)显示该药物具有明显的剂量依赖性疗效:3毫克/千克无效,而10毫克/千克导致性能有中等程度的增强。
本研究结果首次证明了SSR504734在正常生理条件下具有记忆增强作用,进一步支持了其作为认知增强剂的潜力。